<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04166253</url>
  </required_header>
  <id_info>
    <org_study_id>919PP17</org_study_id>
    <nct_id>NCT04166253</nct_id>
  </id_info>
  <brief_title>Protective Role of Vitamin D in Breast Cancer Patients Treated With Doxorubicin</brief_title>
  <acronym>VDDOXO</acronym>
  <official_title>The Potential Protective Effects of Vitamin (D) Against Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Damanhour University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Damanhour University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is aimed at Evaluation of the potential protective effect of Vitamin D in&#xD;
      doxorubucin- induced toxicity in breast cancer patients.&#xD;
&#xD;
      Proposal Steps:&#xD;
&#xD;
        1. 100 Patients recruited from Alexandria Main University Hospital (AMUH), Oncology Unit&#xD;
           are randomly assigned in to two groups:&#xD;
&#xD;
             -  Control group (n=50) the patient will receive AC regimen (Doxorubucin &amp;&#xD;
                cyclophosphamide) for 4 cycles every 21 day (i.e. 3 months.)&#xD;
&#xD;
             -  Vitamin D group (n=50) who will receive 4 Cycles AC regimen in addition to vitamin&#xD;
                D (Bon One 0.5 microgramÂ®) once daily.&#xD;
&#xD;
        2. Echocardiography (Echo) will be done at base line and at the end of the treatment.&#xD;
&#xD;
        3. Vitamin D, LDH, Troponin-t as well as IL-6 will be assessed at baseline and at the end&#xD;
           of the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Research Objectives: Evaluation of the potential protective effect of Vitamin D in&#xD;
      doxorubucin- induced toxicity in breast cancer patients.&#xD;
&#xD;
      Proposal Steps:&#xD;
&#xD;
        1. Assessing breast cancer patients taking part in the study receiving adjuvant&#xD;
           chemotherapy AC (Anthracycline (Doxorubucin)-cyclophosphamide) for breast cancer for 4&#xD;
           cycles every 21 day (i.e. 3 months.)&#xD;
&#xD;
        2. 100 Patients are randomly assigned in to two groups:&#xD;
&#xD;
             -  Control group (n=50) the patient will receive AC regimen (Doxorubucin &amp;&#xD;
                Cyclophosphamide) for 4 cycles every 21 day (i.e. 3 months.)&#xD;
&#xD;
             -  Vitamin D group (n=50) who will receive 4 Cycles AC regimen in addition to vitamin&#xD;
                D once daily.&#xD;
&#xD;
        3. All participants are recruited from AMUH Hospital Oncology Unit. All participants will&#xD;
           be given their consent. The study will be approved by research ethics committee of&#xD;
           Damanhour University.&#xD;
&#xD;
        4. Tumor staging is done according to American joint committee on cancer (TNM staging of&#xD;
           breast cancer eighth edition (Amin et al., 2017).&#xD;
&#xD;
        5. All patients will be submitted to:&#xD;
&#xD;
             -  Full patient history and clinical examination.&#xD;
&#xD;
             -  Routine follow up before and after each chemotherapy cycle (complete blood picture,&#xD;
                liver function tests, renal function tests.&#xD;
&#xD;
        6. Echocardiography (Echo) at base line and at the end of the treatment.&#xD;
&#xD;
        7. Vitamin D, LDH, Troponin-t as well as IL-6 will be assessed at baseline and at the end&#xD;
           of the study.&#xD;
&#xD;
      Methodology:&#xD;
&#xD;
      Venous blood samples will be analyzed using ELISA Vitamin D, IL-6 kits and&#xD;
      immuno-histo-chemistry Troponoin-T and LDH and kits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Actual">May 1, 2020</completion_date>
  <primary_completion_date type="Actual">April 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>2 arms one is a control arm recieving only doxorubucin adjuvant chemotherapy and another intervention arm recieving doxorubucin as well as vitamin D orally once daily for 3 months</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>The participant did not know the exact drug he is using.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Troponin-T in ng/l</measure>
    <time_frame>3 months</time_frame>
    <description>A change in plasma levels of Troponin-T in ng/l</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vitamin D in ng/ml</measure>
    <time_frame>3 months</time_frame>
    <description>A change in plasma levels of Vitamin D in ng / ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LDH in U/L</measure>
    <time_frame>3 months</time_frame>
    <description>A change in plasma levels of LDH in U/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interleukin-6 in MIU/ml</measure>
    <time_frame>3 months</time_frame>
    <description>A change in plasma levels of Interleukin-6 in MIU/ ml</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control group of breast cancer patients will receive adjuvant AC chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention group of breast cancer patients will receive adjuvant AC chemotherapy in addition to vitamin D (alfacalcidol 0.5 mcg orally once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>Alfacalcidol oral tablets once daily</description>
    <arm_group_label>Vitamin D group</arm_group_label>
    <other_name>Alfacalcidol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients has a good performance status (ECOG 0-2) according to eastern cooperative&#xD;
             oncology group (ECOG) score.&#xD;
&#xD;
          -  Adequate complete blood picture patients.&#xD;
&#xD;
          -  Females from (30-65) years of old.&#xD;
&#xD;
          -  Normal renal and liver functions.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Cardiac diseased or reduced cardiac output with left ventricular ejection fraction&#xD;
             less than 50%.&#xD;
&#xD;
          -  Hepatic impaired patients.&#xD;
&#xD;
          -  Pregnancy or breast feeding or child bearing state.&#xD;
&#xD;
          -  Patient with history of allergy to vitamin D.&#xD;
&#xD;
          -  Concomitant use of other vitamins.&#xD;
&#xD;
          -  Renal impaired patients.&#xD;
&#xD;
          -  History of breast cancer.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maged W Helmy, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Professor of Pharmacology, Faculty of pharmacy, Damanhour University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gehan A Khedr, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Assistant Professor of Oncology, Faculty of Medicine, Alexandria University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Noha A El Bassiouny, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Lecturer of Clinical Pharmacy, Faculty of Pharmacy, Damanhour University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mostafa A Mahmoud, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Pharmacy Specialist</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Damnhour university</name>
      <address>
        <city>Beheira</city>
        <zip>22511</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 11, 2019</study_first_submitted>
  <study_first_submitted_qc>November 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2019</study_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Damanhour University</investigator_affiliation>
    <investigator_full_name>Noha El Bassiouny</investigator_full_name>
    <investigator_title>Lecturer of clinical pharmacy</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Alfacalcidol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Summary of data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

